Equites Radar

TNDM · Tandem Diabetes Care, Inc.

Medical DevicesUnited StatesAnalyst view: Buy

$17.12

+3.44% last session

End-of-day data · updated 2026-07-28

Neutral2 bullish · 2 bearish technical signals
Consensus: Buy (2.00 from 19 analysts)
To mean target: +69.9%

Market cap

$1B

Enterprise value

$1B

Trailing P/E

Forward P/E

150.9

Dividend yield

Beta

1.58

Avg volume

2M

Employees

2K

2D change

5D change

1.60%

10D change

0.53%

30D change

5.73%

60D change

-0.17%

MTD change

9.02%

YTD change

-21.88%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)2.00
Covering analysts19
Mean price target$29.08
Low price target$15.50
Upside to mean target+69.9%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)59.2
50-day MA$16.12
200-day MA$18.93
Price vs 50-day MA+10.2%
Price vs 200-day MA-6.2%
MACD histogram0.22
Volume vs 3-month avg0.8×
52w low $10.1152w high $28.26

Analyst sentiment over time — TNDM

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-07-15

Latest call per bank · past 12 months

Deutsche Bank

Hold

$15.50

-9.5% vs price
▲ raised from $0.00Initiates · 2026-06-23

Wells Fargo

Overweight

$27.00

+57.7% vs price
▲ raised from $21.00Upgrade · 2026-06-01

Citigroup

Neutral

$17.00

-0.7% vs price
▼ cut from $22.00Maintains · 2026-05-28

Bank of America

Neutral

$25.00

+46.0% vs price
▼ cut from $35.00Maintains · 2026-05-18

Barclays

Overweight

$55.00

+221.3% vs price
▼ cut from $56.00Maintains · 2026-05-11

Goldman Sachs

Neutral

$25.00

+46.0% vs price
▼ cut from $28.00Maintains · 2026-04-09

Morgan Stanley

Equal-Weight

$25.00

+46.0% vs price
▲ raised from $23.00Maintains · 2026-03-02

UBS

Neutral

$22.00

+28.5% vs price
▲ raised from $17.00Maintains · 2026-02-20

RBC Capital

Outperform

$25.00

+46.0% vs price
▼ cut from $45.00Maintains · 2025-08-07

Recent rating actions

DateFirmActionRatingPrice target
2026-07-15MizuhoMaintainsNeutral$24.00 $20.00
2026-06-23Deutsche BankInitiatesBuyHold$0.00 $15.50
2026-06-01Wells FargoUpgradeEqual-WeightOverweight$21.00 $27.00
2026-05-28CitigroupMaintainsNeutral$22.00 $17.00
2026-05-18Bank of AmericaMaintainsNeutral$35.00 $25.00
2026-05-12BenchmarkInitiatesHold$0.00
2026-05-11Truist SecuritiesReiteratesBuy$35.00 $31.00
2026-05-11BarclaysMaintainsOverweight$56.00 $55.00

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-28

  • RSI (14): RSI is 59 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 10.2% above the 50-day MA ($16.12).
  • Price vs 200-day MA: Trading 6.2% below the 200-day MA ($18.93).
  • MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
  • MACD (12,26,9): MACD histogram is positive (+0.22) — short-term momentum is improving.
  • 52-week range: Price sits between the 52-week low ($10.11) and high ($28.26).

TNDM Price Chart

Loading chart for TNDM

Fundamentals

Revenue (TTM)$1.0B
EBITDA$0M
Free cash flow$0M
Operating cash flow$0M
Book value / share$1.93
Net debt / EBITDA-3.8
WACC11.0%
Revenue growth6.00%
Earnings growth

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

More in Medical Devices

Screen TNDM against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.